Blog
About

0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Role of Renal Prostaglandin E 2 in Chronic Renal Disease Hypertension

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The role played by renal prostaglandin E<sub>2</sub> in the maintenance of hypertension in chronic renal disease has been investigated through studying the response of body weight, blood pressure, glomerular filtration rate (GFR), 24-hour natriuresis, plasma renin activity (PRA), plasma aldosterone and urinary PGE<sub>2</sub> excretion to the administration of indomethacin (2 mg/kg daily, during 3 days). A group of 37 patients diagnosed as having chronic renal parenchymatous disease with creatinine clearance above 25 ml/min was included in the study. 21 of them were hypertensive (BP > 160/95). 27 normotensive volunteers were also studied and considered as the control group. The initial study disclosed similar levels of PGE<sub>2</sub>, PRA and plasma aldosterone in volunteers, normotensive patients and hypertensive patients, although the sodium intake was lower in the last two groups. A positive correlation between PRA and urinary PGE<sub>2</sub> was found both in normotensive (r =0.507, p < 0.01) and in hypertensive patients (r =0.609, p < 0.01). The administration of indomethacin induced a diminution of PRA, plasma aldosterone and urinary PGE<sub>2</sub> levels together with an increase in diastolic blood pressure (p < 0.05–0.01) in both volunteers and patients. The remaining parameters measured did not change in volunteers or in normotensive patients. On the contrary, in hypertensive patients, during indomethacin administration, lower values of creatinine clearance (p < 0.005) and 24-hour natriuresis (p < 0.05) together with an increase in body weight (p < 0.0l) were observed. These results point to the existence of a protective role of renal prostaglandin E<sub>2</sub> upon renal function when hypertension appears in the course of chronic renal parenchymatous disease.

          Related collections

          Author and article information

          Journal
          NEF
          Nephron
          10.1159/issn.1660-8151
          Nephron
          S. Karger AG
          1660-8151
          2235-3186
          1982
          1982
          03 December 2008
          : 32
          : 3
          : 202-206
          Affiliations
          aDepartment of Nephrology, C.S. ‘1° de Octubre’, bDepartment of Endocrinology, Centro ‘Ramon y Cajal, and cDepartment of Experimental Endocrinology, University Complutense Medical School, Madrid, Spain
          Article
          182845 Nephron 1982;32:202–206
          10.1159/000182845
          6759949
          © 1982 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 5
          Categories
          Original Paper

          Cardiovascular Medicine, Nephrology

          Indomethacin, Prostaglandins, Hypertension, Renin, Aldosterone

          Comments

          Comment on this article